127 related articles for article (PubMed ID: 21856202)
1. [Rate of cervical intraepithelial neoplasia before HPV vaccination, Alpes-Maritimes 2006].
Bailly L; Bongain A; Mariné Barjoan E; Sattonnet C; Saos J; Durant ML; Mousteou F; Pradier C
Gynecol Obstet Fertil; 2011 Oct; 39(10):549-53. PubMed ID: 21856202
[TBL] [Abstract][Full Text] [Related]
2. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
3. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
[TBL] [Abstract][Full Text] [Related]
4. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
5. Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan.
Ozawa N; Ito K; Tase T; Shibuya D; Metoki H; Yaegashi N
Tohoku J Exp Med; 2017 Dec; 243(4):329-334. PubMed ID: 29269635
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Cancer Sci; 2011 Apr; 102(4):877-82. PubMed ID: 21251162
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
9. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
[TBL] [Abstract][Full Text] [Related]
10. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
[TBL] [Abstract][Full Text] [Related]
11. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
[TBL] [Abstract][Full Text] [Related]
13. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
14. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
[TBL] [Abstract][Full Text] [Related]
16. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
[TBL] [Abstract][Full Text] [Related]
17. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.
Pollock KG; Kavanagh K; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Cruickshank M; Palmer TJ; Nicoll S; Donaghy M
Br J Cancer; 2014 Oct; 111(9):1824-30. PubMed ID: 25180766
[TBL] [Abstract][Full Text] [Related]
18. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
[TBL] [Abstract][Full Text] [Related]
19. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus infection and cervical neoplasia: is there a protective role against human papillomavirus-related carcinogenesis?
Agorastos T; Chrisafi S; Lambropoulos AF; Mikos T; Constandinides TC; Schlehofer JR; Schlehofer B; Kotsis A; Bontis JN
Eur J Cancer Prev; 2008 Aug; 17(4):364-8. PubMed ID: 18562963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
